The current heart failure clinical trial environment is strained by increasing complexity and cost, regulatory requirements, competing demands on stakeholders, implementation challenges, and decreasing patient and investigator participation.
. This committed community of stakeholders has made major strides to improve patient care, but also recognizes multiple aspects of the clinical research system that need to be improved or reimagined.
FACTORS ADVERSELY AFFECTING HF CLINICAL TRIALS
Although randomized controlled trials are the gold standard for clinical evidence generation, they have become slow, cumbersome, and costly, and often have limited
generalizability. There appears to be a myriad of causes.
1. PATIENT ENGAGEMENT. Poor patient enrollment leads to slow and costly clinical trials (2) . A number of factors influence patients' decisions to participate in clinical research, including trial complexity and burden, a favorable benefit to risk profile for the experimental treatment, and the potential to help others (3). However, patient input has rarely been utilized to improve these issues, and patients may struggle to find accessible information regarding clinical trials, support from members of the HF community with similar phenotypes, and time for discussion about clinical research during clinic visits. (14) . The total cost to develop a novel therapeutic and bring it to market has doubled and is now estimated to exceed $2.5 billion (15) . This growth is linked at least in part to expanding trial complexity associated with outsourcing of services to contract research organizations, with a doubling in personeffort required at each trial site to enroll one-half of the patients (1,16). (22) . Due in part to these changes and differences in trial design, the oncology pipeline currently boasts the largest number of preclinical therapeutics in development of any field (17) .
Some trends in oncology trials are, however, less applicable to the HF ecosystem ( Table 1) . Use of surrogate endpoints and biomarkers has allowed earlier (Table 3) .
Nevertheless, current iterations of pragmatic trials have limitations ( Table 1) . Because pragmatic trials accept the heterogeneity of standard clinical care, they must be large enough to appropriately overcome this variability (36) . Although blinding of treatment allocation and outcome assessment is not typical of real-world care, important safety events other than major outcomes may be altered by unmasked bias. O'Connor et al.
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Pragmatic trials may have difficulty collecting PRO questionnaires, and have had trouble balancing efficiency, rigor, and variable practice patterns that may reduce the ability to detect differential effects of interventions (36) . New analytic methods need to be adopted to interpret data from these novel schemes, in part because incomplete ascertainment and trial drop out may play a larger role, and it may take time before the research community achieves consensus over how to interpret the results. Were there any differences in side effects among sex, race and age?
Subgroup analyses were conducted for sex, race, and age.
The risk of side effects appeared to be similar in men and women.
There was an increased risk of an allergic reaction called angioedema in black patients.
The risk of low blood pressure was higher in patients 65 years and older. Almost 50,000 registrants consented to participate over 8 months, with 81% uploading at least some data; however, only 3% submitted complete data. The Eureka platform, powered by Amazon Web Services, has a currently accessible cohort of over 100,000 subjects, including more than 50% women, and its proportionally few minorities can be enriched in subgroups created for trial purposes (42) . Utilization of similar systems has been associated with 50%
financial savings over conventional strategies (43) .
Novel electronically captured HF clinical trial endpoints may characterize disease impact and drug or device treatment effect better than traditional endpoints, although validation is needed (44) . 
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